Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Review · March 09, 2024

Outcomes of the Targeted Therapy Vismodegib in Patients With Periocular Basal Cell Carcinoma

Ophthalmic Plastic and Reconstructive Surgery

 

Additional Info

Ophthalmic Plastic and Reconstructive Surgery
Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma
Ophthalmic Plast Reconstr Surg 2024 Jan 01;40(1)1-10, T Singalavanija, KS Ceylanoglu, S Juntipwong, BG Beser, VM Elner, FP Worden, H Demirci

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading